Cetuximab is a monoclonal antibody against epidermal growth factor receptor and is used in the treatment of head and neck cancer, non-small cell lung cancer, and colorectal cancer. This case report describes a rare (<1% incidence) side effect of cetuximab administration: aseptic meningitis. We report a case which is, to our knowledge, the only case at the time of submission of this manuscript of aseptic meningitis in a patient being treated for metastatic colon cancer who was not cetuximab-naïve. This case report may help inform clinicians about the identification and outcome of this adverse event.
Erbitux (cetuximab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, 2016.
2.
Wolters Kluwer Clinical Drug Information, Inc. (Lexi-Drugs). Wolters Kluwer Clinical Drug Information, Inc., 2017.
3.
PfeifferPNielsenDBjerregaardJet al.Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol2008; 19: 1141–1145.
4.
Maritazet al.Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event. BMC Cancer2016; 16: 384–384.
5.
Prasanna, et al. More than a headache: a case of cetuximab-induced aseptic meningitis. BMJ Case Rep. Published online 12 May 2015.
